In this context, several studies have reported on the apparent utility of measurement of serum C-reactive protein (CRP), a surrogate for IL-6, as a strategy to predict responsiveness of cancer patients to ICI-targeted immunotherapy. The gene discussed is IL6; the disease is cancer.